3',4',5-Trimethoxy Flavone Derivatives Stimulate Conjunctival Mucus Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye syndrome are primarily symptomatic, providing temporary relief and often accompanied by adverse side effects, and fail to address the root causes of the condition, with a need for a therapeutic agent that can stimulate tear production and mucin secretion while ensuring safety and low side effects.
Innovation Solution
Development of 3',4',5-trimethoxy flavone derivatives and their pharmaceutically acceptable salts, which stimulate conjunctival mucus secretion and inhibit ocular surface damage, formulated into a pharmaceutical composition for the treatment and prevention of dry eye syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional symptomatic therapies (artificial tears, steroid preparations) are used, then temporary relief of dry eye symptoms is achieved, but they do not address the root causes and may cause adverse side effects or require long-term repeated administration
Solution Approach 1:
Instead of suppressing symptoms (anti-inflammatory approach), the invention stimulates the root cause by activating lacrimal glands and conjunctival goblet cells to naturally produce tears and mucin, thereby treating dry eye syndrome from its origin rather than merely alleviating surface symptoms
Solution Approach 2:
The compound enables the body's own lacrimal glands and goblet cells to restore their natural tear and mucin production functions, allowing the physiological system to serve itself rather than relying on external symptomatic relief
2Object-affected harmful factors
If steroid preparations are administered to inhibit inflammatory responses, then inflammatory symptoms are suppressed, but irreversible side effects such as glaucoma may occur upon chronic administration
Solution Approach 1:
Rather than using steroids to suppress inflammation, the invention stimulates the physiological production of protective tears and mucin that naturally lubricate and protect the ocular surface, thereby preventing inflammation through enhanced natural defense mechanisms
Solution Approach 2:
The compound activates the body's own protective mechanisms by stimulating lacrimal glands and goblet cells to produce tears and mucin, allowing the physiological system to defend itself against inflammation without requiring external anti-inflammatory drugs
3Ease of operation
If artificial tear preparations are instilled frequently to provide temporary relief, then short-term symptom relief is achieved, but they require multiple daily applications and provide no protective effects against corneal damage
Solution Approach 1:
The compound is administered once to stimulate the lacrimal glands and goblet cells, which then continuously produce tears and mucin for an extended period, providing prolonged protective effects without requiring frequent re-administration
Solution Approach 2:
By activating the body's own tear and mucin production systems, the compound enables continuous self-generated protection against corneal damage, eliminating the need for repeated external artificial tear applications
Data Source
AI summary
The present invention provides a 3',4',5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. The 3',4',5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.